Canadian regulator approves Thrombogenics eye drug
BRUSSELS Aug 16 (Reuters) - Belgian biotech firm Thrombogenics said Canadian regulator Health Canada had approved its eye drug Jetrea, the first approval the drug has received outside of the United States and Europe.
Outside of the United States, Jetrea is marketed by Novartis unit Alcon, Thrombogenics said.
Jetrea treats symptomatic vitreomacular adhesion, an age-related condition which can lead to blindness. (Reporting by Robert-Jan Bartunek)
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky in Germany after pardon |
- Target probe eyes overseas hackers; stolen cards for sale online
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- Target cyber breach hits 40 million payment cards at holiday peak |